Details of the Drug

General Information of Drug (ID: DMX6RTG)

Drug Name
Trospium
Synonyms
Spasmex; Spasmoplex; Trosec; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
Indication
Disease Entry ICD 11 Status REF
Overactive bladder GC50.0 Approved [1], [2], [3], [4], [5]
Spasm MB47.3 Approved [1], [2], [3], [4], [5]
Therapeutic Class
Parasympatholytics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 392.5
Topological Polar Surface Area (xlogp) 4.4
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The absorption of drug is 9.60% [6]
Clearance
The renal clearance of drug is 29.07 L/h [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [8]
Metabolism
The drug is not metabolised [6]
Vd
The volume of distribution (Vd) of drug is 395 +/- 140 L [7]
Chemical Identifiers
Formula
C25H30NO3+
IUPAC Name
[(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate
Canonical SMILES
C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O
InChI
InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23?
InChIKey
OYYDSUSKLWTMMQ-AIZNXBIQSA-N
Cross-matching ID
PubChem CID
5284632
ChEBI ID
CHEBI:145791
CAS Number
47608-32-2
DrugBank ID
DB00209
TTD ID
D05TIB
ACDINA ID
D00710

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Trospium (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Trospium when combined with Bethanechol. Abnormal micturition [MF50] [20]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Trospium and Oliceridine. Acute pain [MG31] [21]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Trospium and Scopolamine. Addictive disorder [6C50-6C5Z] [22]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Trospium and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [23]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Trospium and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [23]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Trospium and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [22]
Tacrine DM51FY6 Moderate Antagonize the effect of Trospium when combined with Tacrine. Alzheimer disease [8A20] [24]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Trospium and Memantine. Alzheimer disease [8A20] [22]
Galantamine DMEO794 Moderate Antagonize the effect of Trospium when combined with Galantamine. Alzheimer disease [8A20] [24]
Rivastigmine DMG629M Moderate Antagonize the effect of Trospium when combined with Rivastigmine. Alzheimer disease [8A20] [24]
Donepezil DMIYG7Z Moderate Antagonize the effect of Trospium when combined with Donepezil. Alzheimer disease [8A20] [24]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Trospium and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [22]
Promazine DMZAL7W Moderate Additive anticholinergic effects by the combination of Trospium and Promazine. Appearance/behaviour symptom [MB23] [22]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Trospium and Desipramine. Attention deficit hyperactivity disorder [6A05] [22]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Trospium and Cariprazine. Bipolar disorder [6A60] [22]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Trospium and Loperamide. Bowel habit change [ME05] [25]
Sotalol DML60TN Moderate Additive CNS depression effects by the combination of Trospium and Sotalol. Cardiac arrhythmia [BC9Z] [26]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Trospium when combined with Acetylcholine. Cataract [9B10] [27]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Trospium and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [28]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Trospium and Tiotropium. Chronic obstructive pulmonary disease [CA22] [28]
Ipratropium DMFQ320 Moderate Additive anticholinergic effects by the combination of Trospium and Ipratropium. Chronic obstructive pulmonary disease [CA22] [28]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Trospium and Revefenacin. Chronic obstructive pulmonary disease [CA22] [28]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Trospium and Dihydrocodeine. Chronic pain [MG30] [29]
Morphine DMRMS0L Moderate Additive CNS depression effects by the combination of Trospium and Morphine. Chronic pain [MG30] [21]
Alfentanil DMVO0UB Moderate Additive antimotility effects by the combination of Trospium and Alfentanil. Corneal disease [9A76-9A78] [21]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Trospium and Remifentanil. Corneal disease [9A76-9A78] [30]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Trospium and Arbutamine. Coronary atherosclerosis [BA80] [31]
Methadone DMTW6IU Moderate Additive CNS depression effects by the combination of Trospium and Methadone. Cough [MD12] [30]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Trospium and Ethanol. Cystitis [GC00] [32]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Trospium and Trimipramine. Depression [6A70-6A7Z] [22]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Trospium and Cyclobenzaprine. Depression [6A70-6A7Z] [22]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Trospium and Imipramine. Depression [6A70-6A7Z] [22]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Trospium and Nortriptyline. Depression [6A70-6A7Z] [22]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Trospium and OPC-34712. Depression [6A70-6A7Z] [22]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Trospium and Clomipramine. Depression [6A70-6A7Z] [22]
Amitriptyline DMK7F9S Moderate Additive anticholinergic effects by the combination of Trospium and Amitriptyline. Depression [6A70-6A7Z] [22]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Trospium and Amoxapine. Depression [6A70-6A7Z] [22]
Protriptyline DMNHTZI Moderate Additive anticholinergic effects by the combination of Trospium and Protriptyline. Depression [6A70-6A7Z] [22]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Trospium and Doxepin. Depression [6A70-6A7Z] [22]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Trospium and Maprotiline. Depression [6A70-6A7Z] [22]
Nitroglycerin DMQ2491 Minor Decreased dissolution of Trospium taken sublingually caused by Nitroglycerin. Diabetic foot ulcer [BD54] [33]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Trospium and Hyoscyamine. Digestive system disease [DE2Z] [22]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Trospium and Mepenzolate. Digestive system disease [DE2Z] [22]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Trospium and Oxybutynine. Discovery agent [N.A.] [22]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Trospium and Meclizine. Dizziness and giddiness [MB48] [22]
Trihexyphenidyl DMB19L8 Moderate Additive anticholinergic effects by the combination of Trospium and Trihexyphenidyl. Dystonic disorder [8A02] [22]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Trospium and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [34]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Trospium and Diphenhydramine. Episodic vestibular syndrome [AB31] [22]
Timolol DM3NXRU Moderate Altered absorption of Trospium due to GI dynamics variation caused by Timolol. Essential hypertension [BA00] [26]
Bendroflumethiazide DM7EVLC Minor Altered absorption of Trospium due to GI dynamics variation caused by Bendroflumethiazide. Essential hypertension [BA00] [35]
Benzthiazide DMQWZ0H Minor Altered absorption of Trospium due to GI dynamics variation caused by Benzthiazide. Essential hypertension [BA00] [35]
Nadolol DMW6GVL Moderate Antagonize the effect of Trospium when combined with Nadolol. Essential hypertension [BA00] [26]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Trospium and Tolterodine. Functional bladder disorder [GC50] [22]
Darifenacin DMWXLYZ Moderate Additive anticholinergic effects by the combination of Trospium and Darifenacin. Functional bladder disorder [GC50] [22]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Trospium due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [36]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Trospium and Propantheline. Gastric ulcer [DA60] [22]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Trospium when combined with Isoflurophate. Glaucoma [9C61] [27]
Carteolol DMFMDOB Moderate Antagonize the effect of Trospium when combined with Carteolol. Glaucoma [9C61] [26]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Trospium when combined with Pilocarpine. Glaucoma [9C61] [20]
Carvedilol DMHTEAO Moderate Antagonize the effect of Trospium when combined with Carvedilol. Heart failure [BD10-BD1Z] [26]
Chlorothiazide DMLHESP Minor Altered absorption of Trospium due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [35]
Hydroflumethiazide DMVPUQI Minor Altered absorption of Trospium due to GI dynamics variation caused by Hydroflumethiazide. Heart failure [BD10-BD1Z] [35]
Acebutolol DM0TI4U Moderate Antagonize the effect of Trospium when combined with Acebutolol. Hypertension [BA00-BA04] [26]
Bisoprolol DM3UZ95 Moderate Antagonize the effect of Trospium when combined with Bisoprolol. Hypertension [BA00-BA04] [26]
Penbutolol DM4ES8F Moderate Additive CNS depression effects by the combination of Trospium and Penbutolol. Hypertension [BA00-BA04] [26]
Nebivolol DM7F1PA Moderate Antagonize the effect of Trospium when combined with Nebivolol. Hypertension [BA00-BA04] [26]
Pindolol DMD2NV7 Moderate Antagonize the effect of Trospium when combined with Pindolol. Hypertension [BA00-BA04] [26]
Indapamide DMGN1PW Minor Altered absorption of Trospium due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [35]
Trichlormethiazide DMHAQCO Minor Altered absorption of Trospium due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [35]
Labetalol DMK8U72 Moderate Antagonize the effect of Trospium when combined with Labetalol. Hypertension [BA00-BA04] [26]
Atenolol DMNKG1Z Moderate Antagonize the effect of Trospium when combined with Atenolol. Hypertension [BA00-BA04] [26]
Metoprolol DMOJ0V6 Moderate Antagonize the effect of Trospium when combined with Metoprolol. Hypertension [BA00-BA04] [26]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Trospium due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [35]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Trospium and Potassium chloride. Hypo-kalaemia [5C77] [37]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Trospium and Belladonna. Infectious gastroenteritis/colitis [1A40] [22]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Trospium and Amantadine. Influenza [1E30-1E32] [38]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Trospium and Propiomazine. Insomnia [7A00-7A0Z] [22]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Trospium and ITI-007. Insomnia [7A00-7A0Z] [22]
R0-93877 DMM4U9G Moderate Antagonize the effect of Trospium when combined with R0-93877. Irritable bowel syndrome [DD91] [39]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Trospium and Clidinium. Irritable bowel syndrome [DD91] [22]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Trospium and Dicyclomine. Irritable bowel syndrome [DD91] [22]
Physostigmine DM2N0TO Moderate Antagonize the effect of Trospium when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [24]
Propranolol DM79NTF Moderate Additive CNS depression effects by the combination of Trospium and Propranolol. Migraine [8A80] [40]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Trospium and Doxylamine. Morning sickness disorder [SC00] [22]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Trospium when combined with Neostigmine. Myasthenia gravis [8C6Y] [41]
Pyridostigmine DM8HO1L Moderate Antagonize the effect of Trospium when combined with Pyridostigmine. Myasthenia gravis [8C6Y] [41]
Edrophonium DMCRQHB Moderate Antagonize the effect of Trospium when combined with Edrophonium. Myasthenia gravis [8C6Y] [41]
Ambenonium DMOP0BL Moderate Antagonize the effect of Trospium when combined with Ambenonium. Myasthenia gravis [8C6Y] [41]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Trospium and Phenindamine. Nasopharyngitis [CA00] [22]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Trospium and Dimenhydrinate. Nausea/vomiting [MD90] [22]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Trospium and Prochlorperazine. Nausea/vomiting [MD90] [22]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Trospium and Promethazine. Nausea/vomiting [MD90] [22]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Trospium and Cyclizine. Nausea/vomiting [MD90] [22]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Trospium when combined with Metoclopramide. Nausea/vomiting [MD90] [42]
Thiethylperazine DMU3IET Moderate Additive anticholinergic effects by the combination of Trospium and Thiethylperazine. Nausea/vomiting [MD90] [22]
Chlorthalidone DM4DMBT Minor Altered absorption of Trospium due to GI dynamics variation caused by Chlorthalidone. Oedema [MG29] [35]
Metolazone DMB39LO Minor Altered absorption of Trospium due to GI dynamics variation caused by Metolazone. Oedema [MG29] [35]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Trospium and Levomethadyl Acetate. Opioid use disorder [6C43] [43]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Trospium and Pentazocine. Pain [MG30-MG3Z] [21]
Dextropropoxyphene DM23HCX Moderate Additive CNS depression effects by the combination of Trospium and Dextropropoxyphene. Pain [MG30-MG3Z] [43]
Butorphanol DM5KYPJ Moderate Additive antimotility effects by the combination of Trospium and Butorphanol. Pain [MG30-MG3Z] [21]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Trospium and Oxymorphone. Pain [MG30-MG3Z] [21]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Trospium and Levorphanol. Pain [MG30-MG3Z] [21]
Hydromorphone DMHP21E Moderate Additive CNS depression effects by the combination of Trospium and Hydromorphone. Pain [MG30-MG3Z] [30]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Trospium and Dezocine. Pain [MG30-MG3Z] [21]
Codeine DMJX6ZG Moderate Additive antimotility effects by the combination of Trospium and Codeine. Pain [MG30-MG3Z] [21]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Trospium and Flavoxate. Pain [MG30-MG3Z] [22]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Trospium and Nalbuphine. Pain [MG30-MG3Z] [21]
Buprenorphine DMPRI8G Moderate Additive antimotility effects by the combination of Trospium and Buprenorphine. Pain [MG30-MG3Z] [21]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Trospium and Hydrocodone. Pain [MG30-MG3Z] [30]
Acetaminophen DMUIE76 Minor Altered absorption of Trospium due to GI dynamics variation caused by Acetaminophen. Pain [MG30-MG3Z] [44]
Meperidine DMX4GND Moderate Additive antimotility effects by the combination of Trospium and Meperidine. Pain [MG30-MG3Z] [21]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Trospium and Oxycodone. Pain [MG30-MG3Z] [21]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Trospium and Biperiden. Parkinsonism [8A00] [22]
Benztropine DMGZOVN Moderate Additive anticholinergic effects by the combination of Trospium and Benztropine. Parkinsonism [8A00] [23]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Trospium and Procyclidine. Parkinsonism [8A00] [22]
Levodopa DMN3E57 Moderate Altered absorption of Trospium due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [45]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Trospium and Orphenadrine. Parkinsonism [8A00] [22]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Trospium and Methylscopolamine. Peptic ulcer [DA61] [22]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Trospium and Levomepromazine. Psychotic disorder [6A20-6A25] [22]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Trospium and Fluphenazine. Psychotic disorder [6A20-6A25] [22]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Trospium and Triflupromazine. Psychotic disorder [6A20-6A25] [22]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Trospium and Cyproheptadine. Rheumatoid arthritis [FA20] [22]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Trospium and Quetiapine. Schizophrenia [6A20] [22]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Trospium and Mesoridazine. Schizophrenia [6A20] [22]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Trospium and Thioridazine. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Trospium and Aripiprazole. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Trospium and Iloperidone. Schizophrenia [6A20] [22]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Trospium and Paliperidone. Schizophrenia [6A20] [22]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Trospium and Loxapine. Schizophrenia [6A20] [22]
Haloperidol DM96SE0 Moderate Additive anticholinergic effects by the combination of Trospium and Haloperidol. Schizophrenia [6A20] [22]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Trospium and Perphenazine. Schizophrenia [6A20] [22]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Trospium and Molindone. Schizophrenia [6A20] [22]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Trospium and Chlorpromazine. Schizophrenia [6A20] [22]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Trospium and Thiothixene. Schizophrenia [6A20] [22]
Clozapine DMFC71L Moderate Additive anticholinergic effects by the combination of Trospium and Clozapine. Schizophrenia [6A20] [22]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Trospium and Trifluoperazine. Schizophrenia [6A20] [22]
Ziprasidone DMM58JY Moderate Additive anticholinergic effects by the combination of Trospium and Ziprasidone. Schizophrenia [6A20] [22]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Trospium and Risperidone. Schizophrenia [6A20] [22]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Trospium and Asenapine. Schizophrenia [6A20] [22]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Trospium and Pimozide. Schizophrenia [6A20] [22]
Fentanyl DM8WAHT Moderate Additive antimotility effects by the combination of Trospium and Fentanyl. Sensation disturbance [MB40] [21]
Topiramate DM82Z30 Major Increased risk of hyperpyrexia by the combination of Trospium and Topiramate. Substance abuse [6C40] [46]
Pramlintide DM0EZ9Q Moderate Altered absorption of Trospium due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [47]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Trospium and Atropine. Unspecific substance harmful effect [NE6Z] [22]
Nitrofurantoin DM7PQIK Minor Altered absorption of Trospium due to GI dynamics variation caused by Nitrofurantoin. Urinary tract infection [GC08] [48]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Trospium and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [22]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Trospium and Triprolidine. Vasomotor/allergic rhinitis [CA08] [22]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Trospium and Methdilazine. Vasomotor/allergic rhinitis [CA08] [22]
Clemastine DMBZWQL Moderate Additive anticholinergic effects by the combination of Trospium and Clemastine. Vasomotor/allergic rhinitis [CA08] [22]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Trospium and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [22]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Trospium and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [23]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Trospium and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [22]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Trospium and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [22]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Trospium and Acrivastine. Vasomotor/allergic rhinitis [CA08] [22]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Trospium and Azatadine. Vasomotor/allergic rhinitis [CA08] [22]
Disopyramide DM5SYZP Moderate Additive anticholinergic effects by the combination of Trospium and Disopyramide. Ventricular tachyarrhythmia [BC71] [22]
⏷ Show the Full List of 157 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium aluminum silicate E00462 3084116 Adsorbent; Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Trospium 60 mg capsule 60 mg 24 HR Extended Release Oral Capsule Oral
Trospium 20 mg tablet 20 mg Oral Tablet Oral
Trospium 60 mg capsule 60 mg 24 HR Extended Release Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7480).
2 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
3 Trospium chloride: the European experience. Expert Opin Pharmacother. 2006 Jul;7(10):1373-80.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021595.
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
10 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
11 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
12 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
13 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
14 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
15 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
17 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
18 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
20 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
21 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
22 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
23 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
24 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
25 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
26 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27 Multum Information Services, Inc. Expert Review Panel.
28 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
29 Product Information. Lortab (acetaminophen-hydrocodone). Akorn Inc, Buffalo Grove, IL.
30 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
31 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
32 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
33 Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
34 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
35 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
36 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
37 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
38 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
39 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
40 Cerner Multum, Inc. "Australian Product Information.".
41 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
42 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
43 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
44 Clark JM, Seager SJ "Gastric emptying following premedication with glycopyrrolate or atropine." Br J Anaesth 55 (1983): 1195-9. [PMID: 6652009]
45 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
46 Product Information. Topamax (topiramate). Ortho Pharmaceutical Corporation, Raritan, NJ.
47 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
48 Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]